Vulnerable older groups remain a priority for the health department, so no Covid-19 jabs for children for now
The youth is the first of 2 000 South African children taking part in the global trial to test the CoronaVac vaccine
The effectiveness of Covid-19 vaccines is becoming clear from the difference in the number of people admitted to hospital between those who have received at least one vaccine dose and those who have had none
Children from the age of six months to 17 years will take part in vaccine trials
Digital certification looms, but questions remain on implementation, worldwide standardisation, fraud and the ethics of mandatory vaccinations
This content is restricted to subscribers only.
Join the M&G Community
Our commitment at the Mail & Guardian is to ensure every reader enjoys the finest experience. Join the M&G community and support us in delivering in-depth news to you consistently.
Subscribe
Subscription enables:
- – M&G community membership
- – independent journalism
- – access to all premium articles & features
- – a digital version of the weekly newspaper
- – invites to subscriber-only events
- – the opportunity to test new online features first
Already a subscriber?
Login here.
Before forcing employees to be vaccinated the company or employer must consider the constitutional rights of the employees, public health imperatives and the efficient operation of the business
This content is restricted to subscribers only.
Join the M&G Community
Our commitment at the Mail & Guardian is to ensure every reader enjoys the finest experience. Join the M&G community and support us in delivering in-depth news to you consistently.
Subscribe
Subscription enables:
- – M&G community membership
- – independent journalism
- – access to all premium articles & features
- – a digital version of the weekly newspaper
- – invites to subscriber-only events
- – the opportunity to test new online features first
Already a subscriber?
Login here.
Study finds most South Africans rely on healthcare workers for vaccine advice
Experts studying the new variant, C.1.2, are surprised by its substantial mutations but are confident current vaccines will be effective against it
Experts studying the new variant are surprised by its substantial and unexpected mutations but are confident that current vaccines will be effective against it
This content is restricted to subscribers only.
Join the M&G Community
Our commitment at the Mail & Guardian is to ensure every reader enjoys the finest experience. Join the M&G community and support us in delivering in-depth news to you consistently.
Subscribe
Subscription enables:
- – M&G community membership
- – independent journalism
- – access to all premium articles & features
- – a digital version of the weekly newspaper
- – invites to subscriber-only events
- – the opportunity to test new online features first
Already a subscriber?
Login here.
The latest unemployment figures show deepening joblessness and continuous setbacks